Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-α therapy

Annals of Internal Medicine

Volumn 127, Issue 10, 1997, Pages 875-881

  Marcellin, Patrick ^a   Boyer, Nathalie ^a   Gervais, Anne ^a   Martinot, Michèle ^a   Pouteau, Michèle ^a   Castelnau, Corinne ^a   Kilani, Afef ^a   Areias, Jorge ^a   Auperin, Anne ^a   Benhamou, Jean Pierre ^a   Degott, Claude ^a   Erlinger, Serge ^a  

^a BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA INTERFERON; VIRUS RNA;

ADULT; ARTICLE; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER BIOPSY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RNA ANALYSIS;

EID: 15644380122     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-127-10-199711150-00003     Document Type: Article

References (28)

1. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1986;315: 1575-8.
2. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med. 1989;321:1501-6.
3. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989; 321:1506-10.
4. Marcellin P, Boyer N, Giostra E, Degott C, Couroucé AM, Degos F, et al. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology. 1991;13:393-7.
5. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology. 1991;101:497-502.
6. Marcellin P, Pouteau M, Martinot-Peignoux M, Degos F, Duchatelle V, Boyer N, et al. Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology. 1995;109:156-65.
7. Shindo M, Di Bisceglie AM, Cheung L, Shih JW, Cristiano K, Feinstone SM, et al. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med. 1991;115:700-4.
8. Shindo M, Di Bisceglie AM, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon. Hepatology. 1992;15:1013-6.
9. Saracco G, Rosina F, Abate ML, Chiandussi L, Gallo V, Cerutti E, et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-α2b. Hepatology. 1993;18:1300-5.
10. Marcellin P, Boyer N, Degott C, Martinot-Peignoux M, Duchatelle V, Giostra E, et al. Long-term histologic and viral changes in patients with chronic hepatitis C who responded to alpha interferon. Liver. 1994; 14:302-7.
11. Shindo M, Arai K, Sokawa Y, Okuno T. Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-alpha therapy. Ann Intern Med. 1995;122:586-91.
12. Chemello L, Cavalletto L, Casarin C, Bonetti P, Bernardinello E, Pontisso P, et al. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-α in chronic hepatitis C. TriVeneto Viral Hepatitis Group. Ann Intern Med. 1996;124:1058-60.
13. Reichard O, Glaumann H, Fryden A, Norkrans G, Schvarcz R, Sonnerborg A, et al. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology. 1995;21:918-22.
14. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trépo C, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med. 1995;332:1457-62.
15. Benhamou JP, Hopf U, Rizzetto M, Sanchez-Tapias JM, Braconier JH, Buhler H, et al. Long-term lymphoblastoid interferon enhances sustained responses and improves histological activity up to 12 months post-treatment [Abstract]. Hepatology. 1995;22:151A.
16. Bacon BR, Farrell G, Benhamou JP, Hopf U, Barcena R, Feinman V, et al. Lymphoblastoid interferon improves long-term response to a six month course of treatment when compared with recombinant interferon alfa 2b: results of an international trial [Abstract]. Hepatology. 1995;22:152A.
17. Marcellin P, Pouteau M, Boyer N, Degos F, Castelnau C, Degott C, et al. Usefulness of prolonging interferon therapy according to the initial response in patients with chronic hepatitis C without cirrhosis [Abstract]. Hepatology. 1994;20:154A.
18. Young KK, Resnick RM, Myers TW. Detection of hepatitis virus C RNA by a combined reverse transcription-polymerase chain reaction assay. J Clin Microbiol. 1993;31:882-6.
19. Urdea MS, Horn T, Fultz TJ, Anderson M, Running JA, Hamren S, et al. Branched DNA amplification multimers for the sensitive, direct detection of human hepatitis viruses. Nucleic Acids Symp Ser. 1991;24:197-200.
20. Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heuverswyn H, et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol. 1993;74:1093-102.
21. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Bréchot C, et al. A proposed system for the nomenclature of hepatitis C viral genotypes [Letter]. Hepatology. 1994;19:1321-4.
22. Bhattacherjee V, Prescott LE, Pike I, Rodgers B, Bell H, El-Zayadi AR, et al. Use of NS-4 peptides to identify type-specific antibody to hepatitis C virus genotypes 1, 2, 3, 4, 5 and 6. J Gen Virol. 1995;76:1737-48.
23. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1:431-5.
24. Martinot-Peignoux M, Marcellin P, Xu LZ, Bernuau J, Erlinger S, Benhamou JP, et al. Reactivity to c33c antigen as a marker of hepatitis C virus multiplication [Letter]. J Infect Dis. 1992;165:595-6.
25. Di Martino V, Feray C, Saurini F, Samuel D, Gigou M, Reynès M, et al. Quantitation of intra-hepatic HCV RNA according to histology and to genotypes [Abstract]. Hepatology. 1995;22:410A.
26. Kwok S, Higuchi R. Avoiding false positives with PCR. Nature. 1989;339: 237-8.
27. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferon-α on incidence of hepato-cellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995; 346:1051-5
28. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology. 1995;22:1050-6.